153 - ACX-362E for CDI; Cosentyx and inhibition of joint damage progression; new assays from Grifols; personalized optimization of insulin pump therapy; FDA and drug shortages for critical products; FDA guidance on attacks on food supply

New FDA Approvals

153 - ACX-362E for CDI; Cosentyx and inhibition of joint damage progression; new assays from Grifols; personalized optimization of insulin pump therapy; FDA and drug shortages for critical products; FDA guidance on attac...View more